All In Biotech

Drug Trial Radar · NCT03778996

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Phase 2 Clinical Trial to Evaluate Efficacy and Safety of SM-88 Used With Methoxsalen, Phenytoin, and Sirolimus (MPS) as Maintenance Therapy Following Standard Treatments for Ewing's Sarcoma or as Salvage Therapy for Advanced Sarcomas

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Actual

Start

Jan 3, 2020

Primary completion

Dec 19, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Sarcoma Oncology Research Center, LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tyme, Inc
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: * Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic treatment * Clinically advanced sarcoma patients in the salvage treatment setting Up to 24 efficacy evaluable patients (up to 12 per cohort) will be enrolled. Study patients will receive oral SM-88, with scheduled safety and efficacy evaluations.

Conditions

  • Sarcoma, Ewing
  • Sarcoma

Interventions

  • Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)Drug

    Daily oral combination therapy for cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: Every 3 months for up to 2 years
  2. Stable Disease for at Least 3 MonthsTime frame: Every 3 months for up to 2 years
  3. Progression Free Survival on Study of at Least 1.5 Times the Duration of PFS for the Last Prior TreatmentTime frame: Every 3 months for up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sarcoma Oncology Research Center

    Santa Monica, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.